“Having this option available provides optimism and confidence for ADPKD patients in Canada specifically, and around the world,” says Jeff Robertson, Executive Director of the PKD Foundation of Canada. “It is encouraging to see continued positive data related to this treatment and Canadian participation in this trial.”

The trial results are expected to be submitted for presentation at a nephrology medical congress in the second half of 2017.

“These results mean more research, more progress, and more hope for ADPKD patients and their families,” says Daniel G. Bichet, Faculty of Medicine, Université de Montréal. “This trial presented more opportunities for researchers to study tolvaptan and determined additional results proving tolvaptan’s benefit in patients with lower kidney function as well.”

The full announcement can be found at the link here, and a comprehensive review of the results should be available at the 2017 PKD Symposium on November 25^th that will be open for registration shortly.